UK's IP Group HY26 NAV/share rises on Pfizer obesity programme progress

By Reuters News


Overview

  • UK science and tech investor's HY26 NAV/share grew 3.2%, driven by Pfizer obesity asset progress

  • Company reported HY26 profit of £31.2 mln, reversing prior-year loss

  • Cash proceeds from exits in HY26 reached £68.7 mln, surpassing FY25 total


Outlook

  • IP Group targets more than £250m of exits by end-2027

  • Company expects value-driving milestones across portfolio over next 18 months

  • Company sees supportive environment for science and technology investments


Result Drivers

  • PFIZER OBESITY ASSET - £27m uplift in Pfizer Obesity Royalty Income asset valuation following positive clinical progress and reduced development risk

  • EXIT PROCEEDS - Cash proceeds from exits reached £68.7m, with major contributions from Monolith, Hinge Health, and Centessa exits

  • PORTFOLIO FUNDRAISING - Portfolio companies raised £543m from third parties, which the company says validates portfolio quality


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Net Income

GBP 31.20 mln

H1 Net Asset Value

GBP 1.006 bln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the investment management & fund operators peer group is "buy"

  • Wall Street's median 12-month price target for IP Group PLC is GBp114.50, about 74.3% above its September 14 closing price of GBp65.70

  • The stock recently traded at 6 times the next 12-month earnings vs. a P/E of 6 three months ago


Reuters Recommended Reads

  • Sept 14 - Vista Equity exploring strategic options for financial software provider Finastra, sources say

  • Sept 14 - China's DeepSeek hires dealmaker as CFO ahead of possible IPO

  • Sept 14 - JPMorgan to launch long-awaited 'frontier' local currency debt index


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.